Skip to main
LENZ
LENZ logo

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics Inc. has completed a robust clinical program, specifically the CLARITY program, comprising three Phase 3 trials that demonstrated strong efficacy and a favorable safety profile, positioning the company for a potential market-leading role in the treatment of presbyopia. The company anticipates continued growth in annual spending levels, which could sustain momentum into fiscal year 2027 and beyond. Furthermore, LENZ is projected to achieve profitability by 2028, indicating a positive financial outlook and growth potential that could support an expansion of their sales force.

Bears say

LENZ Therapeutics faces significant commercial challenges in the presbyopia treatment sector, particularly related to altering established consumer behavior and the lack of a diversified product pipeline beyond its primary candidate, Vizz. The company must contend with competitive dynamics as well, as other presbyopia treatments are in development, which could affect Vizz’s market position even if those alternatives are currently at an earlier stage. Additionally, there are concerns regarding Vizz's intellectual property protection and the potential need for further funding or partnerships, which could impede the company's ability to maximize the value of its product offerings.

LENZ has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 4 analysts, LENZ has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.